Biogen Reports Strong Q1 Earnings Despite Guidance Cut
Biogen's stock rose 6% after the company reported Q1 2026 revenue of $2.48 billion, surpassing estimates, driven by growth in its 'growth products' portfolio. However, the company lowered its full-year profitability guidance due to expected charges from in-process research and development.
Topics: Biogen Earnings Guidance Adjustment Leqembi Profitability Revenue Growth